Myriad Genetics (MYGN +3.3%) moves up this morning after Goldman upgraded shares to Buy with a...

|About: Myriad Genetics, Inc. (MYGN)|By:, SA News Editor

Myriad Genetics (MYGN +3.3%) moves up this morning after Goldman upgraded shares to Buy with a price target of $29. The firm says reimbursement concerns are overdone, plus the stock should gain added traction from the strength of its pipeline and a potential new dividend.